[Skip to Navigation]
March 1987

Selection of Therapeutic Agents for Intraocular Proliferative Disease: II. Differing Antiproliferative Activity of the Fluoropyrimidines

Author Affiliations

From the Eye Research Institute of Oakland University, Rochester, Mich (Drs Blumenkranz and Hartzer); William Beaumont Hospital, Royal Oak, Mich (Drs Blumenkranz and Hartzer); and Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine (Dr Hajek). Dr Blumenkranz is now with Associated Retina Consultants PC, Royal Oak, Mich.

Arch Ophthalmol. 1987;105(3):396-399. doi:10.1001/archopht.1987.01060030116039

• We confirm the potent antiproliferative effects of the fluoropyrimidines on cellular proliferation in vitro in three different nonmalignant cell types. All fluoropyrimidines tested, except for fluorocytosine, decrease proliferation of human dermal fibroblasts, bovine aortic vascular endothelial cells, and human retinal pigment epithelial cells in vitro. Fluorouridine, an intracellular metabolite of fluorouracil, is nearly 100-fold more potent than fluorouracil and its deoxymetabolite. Human dermal fibroblasts are more sensitive to the inhibitory effects of deoxymetabolites than the cells of either human retinal pigment epithelium or bovine aortic vascular endothelium. Fluorouridine and other fluoropyrimidines may prove to be valuable second-generation drugs in the treatment of intraocular proliferative disorders.